Back to top
more

Neovasc Inc. (NVCN)

(Delayed Data from NSDQ)

$0.50 USD

0.50
470,511

+0.01 (2.96%)

Updated May 3, 2019 03:59 PM ET

After-Market: $0.49 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Will Neovasc (NVCN) Report Negative Q2 Earnings? What You Should Know

by Zacks Equity Research

Neovasc (NVCN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Neovasc (NVCN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Neovasc (NVCN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Neovasc (NVCN) Releases Update on Reducer and Tiara Products

by Zacks Equity Research

Neovasc (NVCN) expects an approval from the FDA for Reducer by end of 2020.

Company News For Jan 2, 2020

by Zacks Equity Research

Companies in the news are: NVCN, VIVE, SDRL, UROV

Neovasc (NVCN) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Neovasc (NVCN) delivered earnings and revenue surprises of 23.77% and -41.18%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

What's in Store for DENTSPLY SIRONA (XRAY) in Q3 Earnings?

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) Q3 earnings to reflect better-than-expected performance at Technology & Equipment and growth in emerging markets.

What's in the Cards for Cardinal Health (CAH) in Q1 Earnings?

by Zacks Equity Research

Cardinal Health (CAH) Q1 earnings are likely to reflect better-than-expected performance at Pharmaceutical and Medical segments.

AmerisourceBergen (ABC) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

AmerisourceBergen's (ABC) Q4 earnings are likely to reflect the better-than-expected performance at Pharmaceutical Distribution and higher revenues.

DexCom (DXCM) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

DexCom's (DXCM) Q3 earnings is likely to reflect top-line growth and rising global awareness of the company's real-time CGM.

Neovasc (NVCN) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Neovasc (NVCN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Nevro (NVRO) Catches Eye: Stock Jumps 6.3%

by Zacks Equity Research

Nevro (NVRO) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Neovasc (NVCN) Looks Good: Stock Adds 7.4% in Session

by Zacks Equity Research

Neovasc (NVCN) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

    Inogen (INGN) Beats Earnings and Revenue Estimates in Q1

    by Zacks Equity Research

    Inogen (INGN) reported a stellar first quarter of 2017, beating the Zacks Consensus Estimate for both the counts. The company witnessed solid growth in revenues and adjusted earnings on a year-over-year basis.

      Abiomed (ABMD) Q4 Earnings Meet, Revenues Beat Estimates

      by Zacks Equity Research

      Abiomed Inc. (ABMD), a leading developer, manufacturer and marketer of medical products, reported fourth-quarter fiscal 2017 earnings of 33 cents per share, which were in line with the Zacks Consensus Estimate.

        DENTSPLY (XRAY) Earnings and Revenues Miss Estimates in Q1

        by Zacks Equity Research

        DENTSPLY SIRONA Inc. (XRAY) reported adjusted earnings per share of 49 cents in the first quarter of 2017, missing the Zacks Consensus Estimate by 2 cents.

          Integer (ITGR) Q1 Earnings Miss, Revenues Beat Estimates

          by Zacks Equity Research

          Integer Holdings Corporation (ITGR) reported adjusted earnings of 41 cents per share in the first quarter of 2017, a penny down on a year-over-year basis.

            Abiomed (ABMD) Q4 Earnings Meet, Revenues Beat Estimates

            by Zacks Equity Research

            Abiomed posted a promising fourth quarter of fiscal 2017, with revenues beating the Zacks Consensus Estimate and earnings meeting the mark.

              Allscripts (MDRX) Beats on Q1 Earnings, Revenues In Line

              by Zacks Equity Research

              Allscripts Healthcare Solutions, Inc. (MDRX) reported first-quarter 2017 earnings of 10 cents per share, beating the Zacks Consensus Estimate by a penny.

                Wright Medical (WMGI) Posts Wider-than-Expected Loss in Q1

                by Zacks Equity Research

                Wright Medical Group N.V. (WMGI) reported adjusted loss of 9 cents per share in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 8 cents.

                  PerkinElmer (PKI) Tops Q1 Earnings Estimates, FY17 View Up

                  by Zacks Equity Research

                  PerkinElmer Inc (PKI) reported first-quarter 2017 adjusted earnings of 55 cents per share, marginally beating the Zacks Consensus Estimate by a penny.

                    athenahealth (ATHN) Earnings, Revenues Miss Estimates in Q1

                    by Zacks Equity Research

                    athenahealth Inc. (ATHN) reported adjusted earnings of 10 cents per share in the first quarter of fiscal 2017.

                      AmerisourceBergen (ABC) Beats on Q2 Earnings, Lags Revenues

                      by Zacks Equity Research

                      AmerisourceBergen Corporation (ABC) posted adjusted earnings of $1.77 per share in the second quarter of fiscal 2017, beating the Zacks Consensus Estimate of $1.71 and increasing 5.4% on a year-over-year basis.

                        DaVita (DVA) Earnings Miss Estimates, Revenues Beat in Q1

                        by Zacks Equity Research

                        DaVita Inc. (DVA) reported first-quarter 2017 adjusted operating earnings of 79 cents per share that missed the Zacks Consensus Estimate of 82 cents.

                          DexCom (DXCM) Q1 Loss Narrower than Expected, Revenues Miss

                          by Zacks Equity Research

                          DexCom Inc. (DXCM) reported a loss of 49 cents per share in the first quarter of 2017, narrower than the Zacks Consensus Estimate of a loss of 55 cents.

                            Ecolab (ECL) Q1 Earnings Miss Estimates, Revenues In Line

                            by Zacks Equity Research

                            Ecolab Inc. (ECL) reported first-quarter 2017 adjusted earnings (excluding special gains, charges and tax items) of 80 cents per share, which missed the Zacks Consensus Estimate of 81 cents.